Pharmafile Logo

Practical advice for Early Scientific Advice (ESA) in HTA submissions

September 26, 2022 | Biopharma, ESA, HTA, Market Access 

A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence generation to support the design of an asset.

- PMLiVE

In recent years, the biopharma market has become progressively complex. As a result, payers are feeling increased pressure to make the right decisions based on the perceived value of each product. Payers must take into consideration not only the clinical efficacy of a drug, but also its safety profile, side effects, and cost-effectiveness, among other factors.

Health Technology Assessment (HTA) is an important tool for decision-makers when it comes to evaluating the clinical effectiveness and cost-effectiveness of new pharmaceutical products and services. There are several barriers that can negatively impact HTA and pricing outcomes, including uncertainty and trials that are not designed with the payers’ evidence needs in mind.

HTA agencies can assist biopharma companies at the early stages of development to ensure they are meeting the expectations of payers. Specifically, HTA agencies offer opportunities to receive early scientific advice (ESA), which involves discussions around key topics such as clinical development programs, economic analyses, and evidence-generation plans. The implementation of the resulting recommendations can reduce payer uncertainty and lead to optimized HTA submissions.

According to Ross Selby, Head of Global Patient Access at Takeda Oncology via NICE: “Uncertainty is the prime reason that medicines struggle with HTA. Scientific advice is a mechanism to reduce that challenge—so take it.”

ESA involves engaging regulatory and/or HTA agencies to provide early-stage feedback on an asset’s clinical development program. While seeking advice from regulators is more common for biopharmaceutical companies, many miss out on the opportunity to speak to payers. The advice can be used to avoid HTA challenges and is confidential and non-binding. However, ESA cannot include feedback on ongoing trials and does not predict the outcome of future HTA appraisals. It is also important to note that ESA cannot include pricing discussions. There are two main types of ESA: HTA agency consultation (involving a single agency) and joint-scientific advice (involving multiple agencies).

Common topics for ESA discussion

The early feedback provided in ESA engagements can save time and money by helping avoid decisions that might later result in unfavorable HTA or pricing outcomes. Some of the most common topics covered in ESA discussions include trial-design optimization, evidence-based value demonstration, payer expectations, design of network meta-analyses, and economic models.

This content was provided by Avalere Health

Company Details

 Latest Content from  Avalere Health 

Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient

As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.

Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities

As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies

Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.

Archetypes: Rethinking go-to-market expectations to drive commercial success

In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer

Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

The challenges of reimbursement and innovative pricing for cell and gene therapies

Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

Fishawack Health welcomes Mario Muredda as its new President of Marketing

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.